You have 9 free searches left this month | to do more

obinutuzumab

Obinutuzumab is a drug used to treat Chronic Lymphocytic Leukemia, Follicular Lymphoma, Small Lymphocytic Lymphoma, and other conditions. Obinutuzumab is being actively studied in 98 studies and prior, has been studied in 40.

Top SponsorsTop SitesTop Investigators
Hoffmann-La RocheHospital Universitari Vall d'Hebron; Servicio de HematologiaJonathon Cohen
Genentech, Inc.M D Anderson Cancer CenterJoseph Tuscano
M.D. Anderson Cancer CenterSamsung Medical CenterMatthew S. Davids, MD
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
Recruiting
  • Mantle Cell Lymphoma
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
2021-04-05
Apr 5, 2021
M
Not yet recruiting
  • Primary Focal Segmental Glomerulosclerosis
  • Obinutuzumab
  • Rochester, Minnesota
    Mayo Clinic in Rochester
2021-10-15
Oct 15, 2021
N
Active, not recruiting
  • Leukemia
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2021-12-01
Dec 1, 2021
K
Suspended
  • Primary CNS Lymphoma
  • Stuttgart, Baden-Württemberg, Germany
    Klinikum Stuttgart
2021-09-15
Sep 15, 2021
A
Not yet recruiting
  • Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
  • (no location specified)
2021-11-23
Nov 23, 2021
I
Not yet recruiting
  • Follicular Lymphoma ( FL)
  • Marginal Zone Lymphoma (MZL)
  • (no location specified)
2021-10-20
Oct 20, 2021
F
Active, not recruiting
  • Waldenstrom Macroglobulinemia
  • Tours, France
    Project manager
2021-06-28
Jun 28, 2021
U
Recruiting
  • Follicular Lymphoma
  • Chicago, Illinois
    University of Chicago Medical Center
2021-11-12
Nov 12, 2021
M
Not yet recruiting
  • Membranous Nephropathy
  • Obinutuzumab
  • Bergamo, BG, Italy
  • +1 more
2021-09-09
Sep 9, 2021
U
Completed
  • Lymphoma, Non-Hodgkin's
  • Obinutuzumab
  • +3 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
2021-04-11
Apr 11, 2021
M
Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
2021-11-18
Nov 18, 2021
O
Completed
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Portland, Oregon
    OHSU Knight Cancer Institute
2021-07-08
Jul 8, 2021
S
Active, not recruiting
  • Follicular Lymphoma
  • Basel, Switzerland
  • +5 more
2021-08-13
Aug 13, 2021
D
Recruiting
  • Graft vs. Host Disease
  • Obinutuzumab
  • Placebo
  • Palo Alto, California
  • +4 more
2021-06-25
Jun 25, 2021
M
Terminated
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-05-21
May 21, 2021
N
Not yet recruiting
  • Follicular Lymphoma
  • +4 more
  • Obinutuzumab
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2021-12-02
Dec 2, 2021
D
Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Stamford, Connecticut
  • +4 more
2021-11-22
Nov 22, 2021
P
Recruiting
  • Follicular Lymphoma
  • Obinutuzumab
  • +2 more
  • Houston, Texas
  • +2 more
2020-11-30
Nov 30, 2020
E
Not yet recruiting
  • Grade 1 Follicular Lymphoma
  • +7 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
2021-08-25
Aug 25, 2021
M
Active, not recruiting
  • Grade 3a Follicular Lymphoma
  • +9 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-07-22
Jul 22, 2021
A
Recruiting
  • Mantle Cell Lymphoma
  • Refractory Lymphoma
  • Boston, Massachusetts
  • +1 more
2021-08-05
Aug 5, 2021
G
Completed
  • B-Cell Chronic Lymphocytic Leukemia
  • B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis)
  • Huixquilucan, Estado De México, Mexico
    Grupo Cooperativo de Hemopatías Malignas
2021-02-01
Feb 1, 2021
S
Terminated
  • Lymphocytic Leukemia, Chronic
  • Lymphoma, Small Lymphocytic
  • IPI-145 (duvelisib)
  • Obinutuzumab
  • La Jolla, California
  • +6 more
2021-03-15
Mar 15, 2021
A
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Columbus, Ohio
    Research Site
2021-09-14
Sep 14, 2021